← DR REDDYS LABORATORIES LTD RDY
Market Price
$12.27
Market Cap
$10.35B
P/E Ratio
N/A
Revenue (FY 2026)
↓-6.1% YoY
$3.58B
3-Yr CAGR: 6.2%
Net Income
↑535,525.0% YoY
$42.85B
Net Margin: 1,196.9%
Free Cash Flow
N/A
FCF Yield: N/A
EPS (Diluted)
N/A
Basic: N/A
Return on Equity
Efficiency
1,057.0%
ROA: 693.9%
⚡ Elevated ROE due to low book equity from buybacks
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (RDY)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2017 | $140,809.0M | — | $78,356.0M | — | — | — | — | — | — | — |
| FY 2018 | $2,181.0M | -98.5% | $1,172.0M | — | — | — | — | — | — | — |
| FY 2019 | $2,225.0M | +2.0% | $1,206.0M | $325.0M | — | — | — | — | — | — |
| FY 2020 | $2,316.0M | +4.1% | $1,247.0M | $239.0M | -26.5% | — | — | — | — | — |
| FY 2021 | $2,594.0M | +12.0% | $1,409.0M | $361.0M | +51.0% | — | — | — | — | — |
| FY 2022 | $2,826.0M | +8.9% | $1,500.0M | $426.0M | +18.0% | — | — | — | — | — |
| FY 2023 | $2,992.0M | +5.9% | $1,695.0M | $734.0M | +72.3% | — | — | — | — | — |
| FY 2024 | $3,350.0M | +12.0% | $1,963.0M | $862.0M | +17.4% | — | — | — | — | — |
| FY 2025 | $3,811.0M | +13.8% | $2,230.0M | $8.0M | -99.1% | — | — | — | — | — |
| FY 2026 | $3,580.0M | -6.1% | $1,889.0M | $42,850.0M | +535,525.0% | — | — | — | — | — |
Valuation
Market Price
$12.27
Market Cap
$10.35B
Enterprise Value
$99.73B
P/E Ratio
N/A
P/B Ratio
2.52
FCF Yield
N/A
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
52.77%
Operating Margin
379.44%
Net Margin
1,196.93%
Return on Equity (ROE)
1,056.98%
Return on Assets (ROA)
693.93%
Asset Turnover
0.58x
Revenue 3-Yr CAGR
6.16%
Financial Health & Liquidity
Current Ratio
0.29
Cash Ratio
0.31
Debt / Equity
22.088
Debt / Assets
14.501
Cash & Equivalents
$164.00M
Total Debt
$89.54B
Book Value / Share
$4.87
Cash Flow Efficiency
Operating Cash Flow
N/A
Capital Expenditures (CapEx)
$249.00M
Free Cash Flow
N/A
OCF / Revenue
N/A
FCF / Revenue
N/A
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
N/A
EPS (Basic)
N/A
Dividends / Share
N/A
Book Value / Share
$4.87
EPS YoY Growth
N/A
Balance Sheet (FY 2026)
Total Assets
$6.17B
Total Liabilities
$2.12B
Stockholders' Equity
$4.05B
Current Assets
$155.00M
Current Liabilities
$537.00M